According to Gram Research analysis, two specific blood markers—high active vitamin D (calcitriol) and poor phosphate retention by the kidneys—independently predict osteoporosis in patients with overactive parathyroid glands better than traditional blood tests. In a 2026 study of 74 patients, about 34% had osteoporosis, and those with elevated calcitriol and impaired renal phosphate reabsorption were significantly more likely to have bone loss, outperforming standard calcium and phosphate measurements.
Researchers studied 74 adults with primary hyperparathyroidism—a condition where the parathyroid glands produce too much hormone—to understand why some develop weak bones while others don’t. They discovered that two specific blood markers were much better at predicting bone loss than the traditional measurements doctors usually check. The active form of vitamin D and how well the kidneys hold onto phosphate were the key factors. About one-third of patients had osteoporosis, and those with higher active vitamin D levels and lower phosphate retention were most at risk. This finding could help doctors identify which patients need more aggressive treatment to protect their bones.
Key Statistics
A 2026 study of 74 adults with primary hyperparathyroidism found that 33.8% had osteoporosis, with elevated calcitriol (active vitamin D) and impaired renal phosphate reabsorption independently predicting bone loss better than traditional blood markers.
Research published in Endocrine Connections showed that in patients with overactive parathyroid glands, calcitriol levels and kidney phosphate handling outperformed serum calcium and phosphate measurements in identifying those at high risk for osteoporosis.
Among 74 patients with primary hyperparathyroidism ineligible for surgery, those with osteoporosis demonstrated significantly higher active vitamin D levels and lower renal phosphate reabsorption compared to non-osteoporotic individuals, according to 2026 research.
The Quick Take
- What they studied: Which blood test results best predict who will develop weak bones (osteoporosis) when they have overactive parathyroid glands
- Who participated: 74 adults diagnosed with primary hyperparathyroidism who were not candidates for surgery. The study looked back at their medical records and blood test results.
- Key finding: Two specific markers—high active vitamin D (calcitriol) and poor phosphate retention by the kidneys—independently predicted osteoporosis better than standard blood tests like calcium and phosphate levels
- What it means for you: If you have overactive parathyroid glands, doctors may soon be able to better predict your bone fracture risk by checking these two specific markers, allowing for earlier and more targeted treatment. However, this finding needs confirmation in larger studies before changing routine clinical practice.
The Research Details
This was a retrospective study, meaning researchers looked back at medical records and blood test results from 74 patients who already had primary hyperparathyroidism. They collected information about various blood markers including calcium, phosphate, vitamin D levels, parathyroid hormone, and how much calcium was lost in urine over 24 hours. They also calculated a special measure of how well the kidneys were holding onto phosphate.
The researchers then used statistical methods to identify which blood markers were most strongly connected to osteoporosis. They tested different cutoff values to find the best numbers that would separate patients with bone loss from those without. This approach allowed them to determine which measurements were the most reliable predictors of bone disease.
Understanding which specific blood markers predict bone loss is crucial because it allows doctors to identify high-risk patients early. Traditional markers like serum calcium and phosphate weren’t distinguishing between patients with and without osteoporosis, so doctors needed better tools. By identifying that active vitamin D and phosphate handling are the key factors, this research provides a more targeted approach to screening and managing bone health in these patients.
This study has both strengths and limitations. The strength is that it focused on specific biochemical mechanisms rather than just general observations. The limitations include the relatively small sample size (74 patients), the retrospective design (which can miss important details), and the fact that all patients were ineligible for surgery, which may not represent all people with this condition. The findings are preliminary and would benefit from confirmation in a larger, prospective study.
What the Results Show
About one-third (33.8%) of the 74 patients studied had osteoporosis. When researchers compared patients with osteoporosis to those without, they found two clear differences: patients with bone loss had significantly higher levels of calcitriol (the active form of vitamin D) and lower renal phosphate reabsorption (meaning their kidneys weren’t holding onto phosphate as well).
Importantly, these two markers remained strongly associated with osteoporosis even when researchers accounted for other factors using advanced statistical analysis. This means the connection was independent and not just due to other variables. In contrast, standard blood tests like total serum calcium, serum phosphate, and 25-hydroxyvitamin D (the storage form of vitamin D) did not differ meaningfully between the two groups, suggesting they are less useful for predicting bone loss in this condition.
The researchers used receiver-operating characteristic (ROC) analysis to identify optimal cutoff values for both calcitriol and phosphate reabsorption. These cutoff values represent the specific numbers that best distinguish between patients with and without osteoporosis, providing practical thresholds that doctors could use in clinical decision-making.
The study also examined 24-hour urinary calcium levels and parathyroid hormone levels, though these were not identified as independent predictors of osteoporosis in the final analysis. The focus on renal phosphate handling (measured as TMP/GFR) was particularly novel, as this aspect of kidney function had not been thoroughly evaluated in previous research on hyperparathyroidism-related bone loss.
Previous research on primary hyperparathyroidism has focused heavily on calcium metabolism and vitamin D status, but the specific role of active vitamin D (calcitriol) and renal phosphate handling had not been clearly defined. This study fills that gap by demonstrating that these two factors outperform traditional biochemical markers. The finding that standard calcium and phosphate measurements don’t distinguish between osteoporotic and non-osteoporotic patients challenges the conventional approach and suggests that more sophisticated analysis of vitamin D metabolism and kidney phosphate handling is needed.
The study has several important limitations. First, it included only 74 patients, which is a relatively small sample size for establishing clinical cutoff values. Second, all participants were ineligible for surgery, which may not represent the full spectrum of people with primary hyperparathyroidism. Third, the retrospective design means some data may have been incomplete or measured inconsistently. Fourth, the study doesn’t establish whether these markers actually predict future fractures—only current bone density status. Finally, the findings need to be validated in an independent group of patients before they can be confidently applied in clinical practice.
The Bottom Line
For patients with primary hyperparathyroidism: Ask your doctor about checking calcitriol (active vitamin D) and renal phosphate handling as part of your bone health assessment. These markers may provide better information about your fracture risk than standard tests alone. For doctors: Consider incorporating calcitriol levels and TMP/GFR measurements into routine evaluation of hyperparathyroidism patients to identify those at highest skeletal risk. Confidence level: Moderate—these findings are promising but need validation in larger studies before becoming standard practice.
This research is most relevant to people diagnosed with primary hyperparathyroidism, particularly those not eligible for surgery. It’s also important for endocrinologists and primary care doctors managing these patients. People with normal parathyroid function should not apply these findings to themselves, as the mechanisms are specific to hyperparathyroidism.
If these markers are incorporated into clinical practice, they could help identify high-risk patients within weeks through blood tests. However, seeing actual improvements in bone health would require months to years of targeted treatment, depending on the interventions used.
Frequently Asked Questions
What is primary hyperparathyroidism and why does it cause weak bones?
Primary hyperparathyroidism occurs when parathyroid glands produce excess hormone, raising blood calcium and increasing bone turnover (breakdown). This accelerated bone remodeling can lead to osteoporosis. The condition affects calcium and phosphate balance, which are essential for bone strength.
How do doctors currently test for bone loss risk in hyperparathyroidism?
Doctors typically check serum calcium, phosphate, and vitamin D levels, plus parathyroid hormone. However, 2026 research shows these standard tests don’t reliably predict osteoporosis. Measuring calcitriol (active vitamin D) and renal phosphate reabsorption (TMP/GFR) are more accurate predictors.
What is calcitriol and why does high level mean higher fracture risk?
Calcitriol is the active form of vitamin D that regulates calcium absorption and bone remodeling. High calcitriol levels increase bone turnover, meaning bones break down faster than they rebuild. This accelerated remodeling weakens bone structure and increases fracture risk.
Can I improve my phosphate reabsorption if I have hyperparathyroidism?
Phosphate reabsorption depends on kidney function and parathyroid hormone levels. Improving it typically requires managing the underlying hyperparathyroidism through surgery (if eligible), medication, or dietary adjustments. Work with your endocrinologist to develop a personalized strategy.
Should I ask my doctor to test my calcitriol levels?
If you have primary hyperparathyroidism, discussing calcitriol and phosphate reabsorption testing with your doctor is reasonable. While these markers show promise in research, they’re not yet standard clinical practice. Your doctor can determine if testing is appropriate for your situation.
Want to Apply This Research?
- Track quarterly blood test results for calcitriol and phosphate reabsorption (TMP/GFR) alongside bone density measurements. Record the specific numerical values and note any changes over time to monitor whether treatment is effectively reducing your osteoporosis risk.
- If your app shows elevated calcitriol levels, work with your doctor to adjust vitamin D supplementation or sun exposure. If phosphate reabsorption is low, discuss dietary phosphate intake and medication adjustments. Set reminders for regular blood work every 3 months to track these specific markers.
- Create a dashboard showing your calcitriol trend line and phosphate reabsorption percentage over time. Compare these to your bone density scan results (DEXA scores) to see if improvements in these markers correlate with improvements in bone health. Share this data with your healthcare provider at each visit.
This article summarizes research findings and should not be interpreted as medical advice. Primary hyperparathyroidism is a serious medical condition requiring professional diagnosis and management. If you have been diagnosed with hyperparathyroidism or osteoporosis, consult with your endocrinologist or primary care physician before making any changes to your treatment plan. The findings presented are preliminary and based on a single study of 74 patients; larger confirmatory studies are needed before these markers become standard clinical practice. Do not use this information to self-diagnose or self-treat.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.